Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004832|
Recruitment Status : Completed
First Posted : February 25, 2000
Last Update Posted : March 25, 2015
OBJECTIVES: I. Evaluate the safety and effectiveness of 3,4-diaminopyridine (DAP) in the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS).
II. Determine the side-effects and benefits associated with DAP.
|Condition or disease||Intervention/treatment|
|Lambert-Eaton Myasthenic Syndrome||Drug: 3,4-diaminopyridine|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||26 participants|
|Study Start Date :||August 1994|
|Estimated Study Completion Date :||June 1998|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004832
|Study Chair:||Donald B. Sanders||Duke University|